Semaglutide goes beyond appetite control by enhancing the bodys response to insulin, a crucial hormone in blood sugar regulation
Cancer Cell 35 , 830849 (2019)
Eur J Immunol 44(10):29032917 DeFuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR et al (2013) B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile
Gall bladder/bile duct disease Acute pancreatitis and other pancreatic disorders have been reported, though the relationship to treatment is unclear Injection-site reactions Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Primary mechanism(s) of action Selectively binds and activates both GIP and GLP-1 receptors Example Tirzepatide (Mounjaro) Dosage Initial: 2.5 mg subcutaneous injection once weekly, titrated up to 5 mg weekly after 4 weeks If additional glycemic control is needed, dosage can be increased in 2.5 mg increments after at least 4 weeks on the current dosage
Key unknowns include: Whether the heart rate increase persists, resolves or has any long-term cardiovascular implications The full effect on liver and metabolic health over extended treatment Whether bone density is affected (significant weight loss can reduce bone mineral density regardless of the method) Any potential effects on the pancreas pancreatitis has been a monitored concern across all GLP-1 medications What happens when someone stops taking retatrutide (weight regain patterns, metabolic rebound) Phase 3 trials, including the large TRIUMPH programme, are designed to answer many of these questions
